前列腺导管腺癌的诊断与治疗新进展

李林

doi:10.13201/j.issn.1001-1420.2022.11.016

前列腺导管腺癌的诊断与治疗新进展

李林^1, ,

- 华东师范大学附属芜湖医院泌尿外科(安徽芜湖，241000)

详细信息

通讯作者: 李林，E-mail: lin_1021@163.com

中图分类号: R737.25

收稿日期: 2021-05-30

刊出日期: 2022-11-06

New advances in diagnosis and treatment of prostate ductal adenocarcinoma

LI Lin^1, ,

- Department of Urology, Wuhu Hospital, East China Normal University, Wuhu, Anhui, 241000, China

More Information

Corresponding author: LI Lin, E-mail: lin_1021@163.com

Received Date: 30 May 2021

Publish Date: 06 November 2022

摘要

摘要: 前列腺导管腺癌(PDA)为前列腺癌少见的类型，其发现及提出已有多年，但因为其病例较少，因此对其诊疗缺少共识。随着其概念的明确，国内、外对PDA的研究逐渐深入，本文对PDA的概念、穿刺活检、病理组织细胞学表现及免疫组化诊断、临床表现、治疗等方面的研究及进展等加以综述。
- 前列腺导管腺癌 /
- 早期诊断 /
- 治疗
Abstract: Ductal adenocarcinoma of the prostate is a rare type of prostate cancer. It has been discovered and proposed for many years, but there is no consensus on its diagnosis and treatment due to the small number of cases. At present, as its concept becomes clear, there are more and more studies on it at home and abroad. In this paper, the concept, puncture biopsy, pathological histological and cytological manifestations, immunohistochemical diagnosis, clinical manifestations and treatment of prostate ductal adenocarcinoma are reviewed.
- prostate ductal adenocarcinoma /
- early diagnosis /
- treatment

HTML全文

参考文献(25)

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	邓通, 蔡林, 陈征, 等. 1990年与2017年中国前列腺癌疾病负担分析[J]. 医学新知, 2020, 30(4): 252-259. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXZ202004002.htm
[3]	高瑞松, 周青, 张晓波, 等. 湖南部分地区2877例前列腺癌患者临床流行病学特征及流行学趋势分析[J]. 中华男科学杂志, 2020, 26(4): 309-315. https://www.cnki.com.cn/Article/CJFDTOTAL-NKXB202004005.htm
[4]	王建文, 谢大炜, 路军, 等. 前列腺导管腺癌临床诊治分析(附21例报告)[J]. 临床泌尿外科杂志, 2020, 35(9): 704-708. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202009008.htm
[5]	Melicow MM, Pachter MR. Endometrial carcinoma of prostatic utricle(uterus masculinus)[J]. Cancer, 1967, 20(10): 1715-1722. doi: 10.1002/1097-0142(196710)20:10<1715::AID-CNCR2820201022>3.0.CO;2-E
[6]	Bergamin S, Eade T, Kneebone A, et al. Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour[J]. Clin Oncol(R Coll Radiol), 2019, 31(2): 108-114. doi: 10.1016/j.clon.2018.10.011
[7]	Iakymenko OA, Lugo I, Kwon D, et al. Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma[J]. Urology, 2020, 137: 108-114. doi: 10.1016/j.urology.2019.10.014
[8]	Au S, Villamil CF, Alaghehbandan R, et al. Prostatic ductal adenocarcinoma with cribriform architecture has worse prognostic features than non-cribriform-type[J]. Ann Diagn Pathol, 2019, 39: 59-62. doi: 10.1016/j.anndiagpath.2019.02.007
[9]	李鹏昊, 杨同, 张志宏, 等. 前列腺导管腺癌诊疗分析(附6例报道)[J]. 天津医科大学学报, 2016, 22(2): 150-153. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYK201602020.htm
[10]	Coffey N, Schieda N, Cron G, et al. Multi-parametric(mp)MRI of prostatic ductal adenocarcinoma[J]. J Magn Reson Imaging, 2015, 41(6): 1639-1645. doi: 10.1002/jmri.24694
[11]	刘英娜, 蒋智铭, 冷冬妮, 等. 前列腺导管腺癌42例临床病理分析[J]. 临床与实验病理学杂志, 2010, 26(6): 704-706. doi: 10.3969/j.issn.1001-7399.2010.06.018
[12]	束坤鹏, 魏强, 李响, 等. 罕见转移性前列腺导管腺癌的多学科综合诊治——泌尿肿瘤MDT在临床诊治中的关键作用[J]. 现代泌尿外科杂志, 2016, 21(12): 950-955. doi: 10.3969/j.issn.1009-8291.2016.12.014
[13]	Jang WS, Shin SJ, YoonCY, et al. Prognostic significance of theproportion of ductal component in ductal adenocarcinoma of the prostate[J]. J Urol, 2019, 197(4): 1048-1053.
[14]	Knipper S, Preisser F, Mazzone E, et al. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study[J]. Clin Genitourin Cancer, 2019, 17(3): 231-237.e2.
[15]	刘坦坦, 贾旭春, 王映梅, 等. 前列腺导管腺癌临床病理分析及文献复习[J]. 现代肿瘤医学, 2017, 5(25): 1430-1435. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201709023.htm
[16]	付娟娟, 宋新兰, 胡小萍, 等. 13例前列腺导管腺癌临床病理分析[J]. 临床与病理杂志, 2015, 35(6): 1117-1120. https://www.cnki.com.cn/Article/CJFDTOTAL-WYSB201506049.htm
[17]	Patil PA, McKenney JK, Reynolds JP, et al. Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate[J]. Histol Histopathol, 2019, 34(4): 381-390.
[18]	傅江河, 陈丽阳, 茅育蕾. 前列腺导管腺癌免疫组化染色分析[J]. 浙江实用医学, 2017, 22(6): 431-433. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSA201706014.htm
[19]	韩文华. 细胞质基因PTEN蛋白缺失用于高级别前列腺上皮内瘤与前列腺导管癌的鉴别价值[J]. 中国老年学杂志, 2016, 36(9): 2168-2171. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201609055.htm
[20]	彭超, 张俊, 徐晓健, 等. 前列腺导管腺癌临床特点和诊治方法分析及文献复习(附7例报告)[J]. 现代泌尿生殖肿瘤杂志, 2018, 10(4): 236-240. https://www.cnki.com.cn/Article/CJFDTOTAL-PXDM201804012.htm
[21]	Ranasinghe W, Brooks NA, Elsheshtawi MA, et al. Patterns of metastases of prostatic ductal adenocarcinoma[J]. Cancer, 2020, 126(16): 3667-3673.
[22]	周明, 甘卫东, 燕翔, 等. 前列腺导管腺癌八例临床分析[J/OL]. 中华临床医师杂志(电子版), 2013, 7(10): 4247-4250.
[23]	Park CK, Shin SJ, Cho YA, et al. HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker[J]. Sci Rep, 2019, 9(1): 20205.
[24]	Morrison GJ, Goldkorn A. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer[J]. Curr Oncol Rep, 2018, 20(4): 35.
[25]	Tao W, Jinge Z, Zhenhua L, et al. Does ductal adenocarcinoma of the prostate(DA)have any prognostic impact on patients with de novo metastatic prostate cancer?[J]. Prostate, 2019, 79(14): 1673-1682.